Sarepta Therapeutics Inc. fell Monday after reporting its embattled gene therapy is expected to miss fourth-quarter sales estimates.
The company said preliminary sales of Elevidys, a therapy to treat a fatal muscle disorder, were $110 million in the last three months of 2025. That compares to the $122 million average estimate expected by Wall Street.
Shares declined as much as 15.2% in New York on Monday.
The company said the Elevidys results were impacted by a bad flu season at the end of 2025, forcing it to reschedule infusions for six patients. Sarepta didn’t provide a detailed guidance range for ...
